The PRISM Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults With Advanced Cancer
PRISM-AC
The Promoting Resilience in Stress Management (PRISM) Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults With Advanced Cancer
3 other identifiers
interventional
195
1 country
5
Brief Summary
Multi-Site Randomized Controlled Trial testing the efficacy of the Promoting Resilience in Stress Management (PRISM) intervention among Adolescents and Young Adults with Advanced Cancer
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable cancer
Started Apr 2019
Longer than P75 for not_applicable cancer
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 15, 2018
CompletedFirst Posted
Study publicly available on registry
September 12, 2018
CompletedStudy Start
First participant enrolled
April 15, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 23, 2024
CompletedResults Posted
Study results publicly available
October 24, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
October 31, 2025
CompletedDecember 5, 2025
December 1, 2025
4.8 years
August 15, 2018
September 12, 2024
December 1, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Pediatric Quality of Life Cancer Module
Pediatric Quality of Life (PedsQL) Cancer Module -This scale was designed to assess pediatric cancer-specific health related quality of life. This is a 27 item scale, with each item rated on a 5-point Likert scale where 0=never and 4=almost always. Higher scores represent better health-related quality of life. Scale range is 0-100.
3-months
Secondary Outcomes (3)
Hospital Anxiety and Depression Scale (HADS) Total Score
3-months
Snyder Hope Scale
3-months
Connor Davidson Resilience Scale
3-months
Study Arms (2)
Promoting Resilience in Stress Management (PRISM)
EXPERIMENTALResilience Skills Training
Usual Care
NO INTERVENTIONStandard psychosocial care
Interventions
Manualized skills training targeting resilience resources: stress-management, goal-setting, cognitive reframing, and meaning-making
Eligibility Criteria
You may qualify if:
- Age 12-24 years
- Diagnosed with advanced cancer: progressive, recurrent, refractory disease or any diagnosis with estimated overall survival \<50% at least 2 weeks prior to enrollment
- Able to speak English
- Able to read English or Spanish
- Cognitively able to participate in interviews
You may not qualify if:
- Patient Refusal
- Parent Refusal (if patient \<18 years-old)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Baylor College of Medicinecollaborator
- Seattle Children's Hospitalcollaborator
- National Cancer Institute (NCI)collaborator
- Children's Hospital Los Angelescollaborator
- Dana-Farber Cancer Institutelead
- University of Pittsburgh Medical Centercollaborator
Study Sites (5)
Children's Hospital Los Angeles
Los Angeles, California, 900278, United States
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
Texas Children's Hospital
Houston, Texas, 77030, United States
Seattle Children's Hospital
Seattle, Washington, 98145, United States
Related Publications (4)
Rosenbaum ARP, Ream M, Fladeboe KM, Lau N, Yi-Frazier JP, Rosenberg AR. Examining Sociodemographic Differences in Response to Resilience Coaching for Adolescents and Young Adults Receiving Hematopoietic Cell Transplantation-A Post Hoc Analysis of the PRISM Intervention. Pediatr Blood Cancer. 2025 Nov;72(11):e31998. doi: 10.1002/pbc.31998. Epub 2025 Aug 31.
PMID: 40887863DERIVEDRosenberg AR, Fladeboe KM, Zhou C, Bradford MC, Kang T, Maurer S, Freyer DR, Baker KS, Comiskey L, Junkins CC, Taylor MR, Yi-Frazier JP. Promoting Resilience in Stress Management: A Randomized Controlled Trial of a Novel Psychosocial Intervention for Adolescents and Young Adults With Advanced Cancer. JCO Oncol Pract. 2026 Feb;22(2):243-254. doi: 10.1200/OP-25-00161. Epub 2025 Apr 28.
PMID: 40294356DERIVEDO'Daffer A, Comiskey L, Scott SR, Zhou C, Bradford MC, Yi-Frazier JP, Rosenberg AR. Protocol for the promoting resilience in stress management (PRISM) intervention: a multi-site randomized controlled trial for adolescents and young adults with advanced cancer. BMC Palliat Care. 2023 May 16;22(1):60. doi: 10.1186/s12904-023-01179-4.
PMID: 37189149DERIVEDO'Daffer A, Comiskey L, Scott SR, Zhou C, Bradford MC, Yi-Frazier JP, Rosenberg AR. Protocol for The Promoting Resilience in Stress Management (PRISM) Intervention: a multi-site randomized controlled trial for adolescents and young adults with advanced cancer. Res Sq [Preprint]. 2023 Apr 7:rs.3.rs-2748874. doi: 10.21203/rs.3.rs-2748874/v1.
PMID: 37066150DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Dr. Abby Rosenberg
- Organization
- Dana Farber Cancer Institute
Study Officials
- PRINCIPAL INVESTIGATOR
Abby R Rosenberg, MD, MS, MA
Dana-Farber Cancer Institute
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
August 15, 2018
First Posted
September 12, 2018
Study Start
April 15, 2019
Primary Completion
January 23, 2024
Study Completion
October 31, 2025
Last Updated
December 5, 2025
Results First Posted
October 24, 2024
Record last verified: 2025-12
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- Data can be shared no earlier than 1 year following the date of publication
- Access Criteria
- DFCI - Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu
The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.